Analysts think NERV stock price could increase by 85%
Aug 28, 2024, 6:26 AM
-1.45%
What does NERV do
Minerva Neurosciences, a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focuses on developing treatments for central nervous system diseases, including roluperidone for schizophrenia and MIN-301 for Parkinson's disease. Founded in 2014, it employs 9 people and co-developed seltorexant for insomnia and major depressive disorder.
3 analysts think NERV stock price will increase by 84.78%. The current median analyst target is $5.10 compared to a current stock price of $2.76. The lowest analysts target is $5.05 and the highest analyst target is $5.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
